EA199900200A1 - Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида - Google Patents

Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида

Info

Publication number
EA199900200A1
EA199900200A1 EA199900200A EA199900200A EA199900200A1 EA 199900200 A1 EA199900200 A1 EA 199900200A1 EA 199900200 A EA199900200 A EA 199900200A EA 199900200 A EA199900200 A EA 199900200A EA 199900200 A1 EA199900200 A1 EA 199900200A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
benzolsulfonamide
isoxazol
phenyl
crystal form
Prior art date
Application number
EA199900200A
Other languages
English (en)
Other versions
EA001472B1 (ru
Inventor
Джон Дж. Тэлли
Джон Р. Медич
Кэтлин Т. Маклофлин
Генри Т. Год
Эдвард Э. Йонан
Original Assignee
Джи. Ди. Сирл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи. Ди. Сирл Энд Ко. filed Critical Джи. Ди. Сирл Энд Ко.
Publication of EA199900200A1 publication Critical patent/EA199900200A1/ru
Publication of EA001472B1 publication Critical patent/EA001472B1/ru

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Power Engineering (AREA)
  • Computer Hardware Design (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Описана стабильная кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамида. Эта кристаллическая структура, названная формой В, является более стабильной, отличается более благоприятными технологическими свойствами и характеризуется температурой плавления, дифракционной картиной рентгеновских лучей и другими физическими параметрами.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900200A 1996-08-14 1997-08-12 Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида EA001472B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14
PCT/US1997/015126 WO1998006708A1 (en) 1996-08-14 1997-08-12 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide

Publications (2)

Publication Number Publication Date
EA199900200A1 true EA199900200A1 (ru) 1999-06-24
EA001472B1 EA001472B1 (ru) 2001-04-23

Family

ID=21820280

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900200A EA001472B1 (ru) 1996-08-14 1997-08-12 Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида
EA200000891A EA003754B1 (ru) 1996-08-14 1997-08-12 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамид

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200000891A EA003754B1 (ru) 1996-08-14 1997-08-12 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамид

Country Status (39)

Country Link
US (2) US6441014B2 (ru)
EP (2) EP1283203A1 (ru)
JP (2) JP3631763B2 (ru)
KR (1) KR100383148B1 (ru)
CN (1) CN1205193C (ru)
AP (1) AP1055A (ru)
AR (1) AR009244A1 (ru)
AT (1) ATE228117T1 (ru)
AU (1) AU722072B2 (ru)
BG (1) BG64259B1 (ru)
BR (1) BR9711151A (ru)
CA (1) CA2264104A1 (ru)
CZ (1) CZ297679B6 (ru)
DE (1) DE69717281T2 (ru)
DK (1) DK0920422T3 (ru)
EA (2) EA001472B1 (ru)
EE (1) EE04237B1 (ru)
ES (1) ES2188971T3 (ru)
GE (1) GEP20022636B (ru)
HK (1) HK1023125A1 (ru)
HU (1) HUP0400923A3 (ru)
IL (2) IL161224A0 (ru)
IS (1) IS1989B (ru)
LT (1) LT4551B (ru)
LV (1) LV12274B (ru)
NO (1) NO312461B1 (ru)
NZ (1) NZ334132A (ru)
OA (1) OA11298A (ru)
PL (1) PL191313B1 (ru)
PT (1) PT920422E (ru)
RO (1) RO120771B1 (ru)
RS (1) RS49671B (ru)
SI (1) SI9720059B (ru)
SK (1) SK283558B6 (ru)
TR (1) TR199900298T2 (ru)
TW (1) TW527350B (ru)
UA (1) UA52684C2 (ru)
WO (1) WO1998006708A1 (ru)
ZA (1) ZA977314B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
WO2000029022A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
MXPA01008903A (es) * 1999-03-01 2003-07-21 Johnson & Jonhson Composicion que comprende un material de tramadol y un farmaco inhibidor de cox-2 selectivo.
EP1210118B1 (en) 1999-08-20 2004-12-08 Ortho-McNeil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
AU7331300A (en) * 1999-08-27 2001-03-26 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
CN100364991C (zh) 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
AU2003238668A1 (en) 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (en) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Form a of valdecoxib suitable for pharmaceutical formulations
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1612203B1 (en) * 2004-06-28 2007-08-01 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
EP2026790A2 (en) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2212836C (en) * 1995-02-13 2003-08-12 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
AU2003238668A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Also Published As

Publication number Publication date
JP2005015497A (ja) 2005-01-20
SK13699A3 (en) 1999-07-12
AP9901458A0 (en) 1999-03-31
JP2000506542A (ja) 2000-05-30
HUP0400923A3 (en) 2007-11-28
LT99024A (en) 1999-07-26
JP3631763B2 (ja) 2005-03-23
LT4551B (lt) 1999-10-25
AU4093697A (en) 1998-03-06
NO990541D0 (no) 1999-02-05
YU7499A (sh) 2000-03-21
BG64259B1 (bg) 2004-07-30
DK0920422T3 (da) 2003-03-17
PT920422E (pt) 2003-03-31
BR9711151A (pt) 1999-08-17
EE04237B1 (et) 2004-02-16
GEP20022636B (en) 2002-02-25
KR20000029994A (ko) 2000-05-25
LV12274B (en) 1999-09-20
AR009244A1 (es) 2000-04-12
BG103155A (en) 1999-11-30
SI9720059A (sl) 1999-12-31
EA001472B1 (ru) 2001-04-23
EP0920422B1 (en) 2002-11-20
KR100383148B1 (ko) 2003-05-09
ES2188971T3 (es) 2003-07-01
OA11298A (en) 2003-10-22
US20010003752A1 (en) 2001-06-14
SI9720059B (sl) 2011-11-30
EE9900053A (et) 1999-08-16
NO990541L (no) 1999-02-05
PL191313B1 (pl) 2006-04-28
ZA977314B (en) 1998-08-14
TR199900298T2 (xx) 1999-05-21
AU722072B2 (en) 2000-07-20
EA003754B1 (ru) 2003-08-28
NZ334132A (en) 2000-06-23
WO1998006708A1 (en) 1998-02-19
HUP0400923A2 (hu) 2004-08-30
RO120771B1 (ro) 2006-07-28
LV12274A (lv) 1999-05-20
AP1055A (en) 2002-04-04
IS1989B (is) 2005-02-15
UA52684C2 (ru) 2003-01-15
IL128255A0 (en) 1999-11-30
TW527350B (en) 2003-04-11
CA2264104A1 (en) 1998-02-19
EP1283203A1 (en) 2003-02-12
IL128255A (en) 2004-06-20
RS49671B (sr) 2007-11-15
CN1233243A (zh) 1999-10-27
CN1205193C (zh) 2005-06-08
SK283558B6 (sk) 2003-09-11
DE69717281T2 (de) 2003-09-04
IL161224A0 (en) 2004-09-27
NO312461B1 (no) 2002-05-13
HK1023125A1 (en) 2000-09-01
US6441014B2 (en) 2002-08-27
US20030004200A1 (en) 2003-01-02
ATE228117T1 (de) 2002-12-15
PL331607A1 (en) 1999-08-02
IS4961A (is) 1999-01-29
CZ33499A3 (cs) 1999-06-16
EP0920422A1 (en) 1999-06-09
US7135489B2 (en) 2006-11-14
CZ297679B6 (cs) 2007-03-07
DE69717281D1 (de) 2003-01-02
EA200000891A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
EA199900200A1 (ru) Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил]бензолсульфонамида
ES2163638T3 (es) Nuevas n-(1-alquil-5-fenil-2,3,4,5-tetrahidro-1h-benzo(b)(1,5)diacepin-3-il)acetamidas.
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
NO2009009I2 (no) Tocilizumab
ATE447002T1 (de) Flüssigkristallines medium
ATE235472T1 (de) N-(2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepi - 3-yl)-3-amide
DK0532515T3 (da) Fremstilling af substituerede piperidiner
EA200000728A1 (ru) Замещенные 2-бензиламино-2-фенилацетамидные соединения
DK0954521T3 (da) 4-[(thien-3-yl)methyl]-imidazoler med alfa2-adrenoceptor-agonistisk aktivitet
EA199800034A1 (ru) Способ получения n-монозамещенных и n,n'-дизамещенных асимметричных циклических мочевин
ES458557A1 (es) Un procedimiento de preparacion de derivados de quinazolina.
ES2194102T3 (es) Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
DE69731735D1 (de) Optischer resonator mit spiralförmigen optischen elementen
EA199900235A1 (ru) Аморфные бензотиофены, способы получения и способы применения
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
EA199900241A1 (ru) ЗАМЕЩЕННЫЕ 1,2,3,4-ТЕТРАГИДРО-2-ДИБЕНЗОФУРАНАМИНЫ И 2-АМИНОЦИКЛОГЕПТА [b] БЕНЗОФУРАНЫ
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling
EA200001050A1 (ru) Малеат пароксетина
DK463885D0 (da) Indomethacin- eller oxicam-baseret anti-inflammatorisk praeparat
ES2173198T3 (es) Derivados de acido propenoico sustituidos con heterociclos, como antagonistas de nmda.
EA199800087A1 (ru) Промежуточное соединение для получения артропоцидного оксадиазина
DK401287A (da) Fremgangsmaade til fremstilling af opstisk aktive forbindelser
SU703090A1 (ru) Способ профилактики послеоперационных артрогенных контрактур
FI960588A (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
DK356183D0 (da) Salte af 1,2,3,4-tetrahydro-beta-carboliner og fremgangsmade til fremstilling deraf

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM